CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Positive
AI Analysis

Summary

Boulevard, co-founded by researcher Georg Schett and ex-Sanofi CSO Frank Nestle, raised $65M to advance a portfolio of targeted antibodies for autoimmune disease treatment.

Importance:5/10
Sentiment:
0.60
startupfundingautoimmuneantibodiestherapeutic
Related Companies

Read the original article

Published by BioPharma Dive on August 12, 2026 10:30 AM

Read Original